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Bacterial glycosyltransferases (GT) often synthesize the same glycan linkages as mam-
malian GT; yet, they usually have very little sequence identity. Nevertheless, enzymatic
properties, folding, substrate specificities, and catalytic mechanisms of these enzyme pro-
teins may have significant similarity. Thus, bacterial GT can be utilized for the enzymatic
synthesis of both bacterial and mammalian types of complex glycan structures. A compar-
ison is made here between mammalian and bacterial enzymes that synthesize epitopes
found in mammalian glycoproteins, and those found in the O antigens of Gram-negative
bacteria.These epitopes includeThomsen–Friedenreich (TF orT) antigen, blood group O, A,
and B, type 1 and 2 chains, Lewis antigens, sialylated and fucosylated structures, and poly-
sialic acids. Many different approaches can be taken to investigate the substrate binding
and catalytic mechanisms of GT, including crystal structure analyses, mutations, compar-
ison of amino acid sequences, NMR, and mass spectrometry. Knowledge of the protein
structures and functions helps to design GT for specific glycan synthesis and to develop
inhibitors. The goals are to develop new strategies to reduce bacterial virulence and to
synthesize vaccines and other biologically active glycan structures.
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INTRODUCTION
Glycans play important roles in most biological processes in health
and disease. Bacteria and human beings have a close relationship
in the intestine, which can be symbiotic or pathogenic. Bacteria
often produce human-like glycan structures with bacteria-specific
glycosyltransferases (GT)s that have given them a selective advan-
tage for adhesion, colonization, and survival. Knowledge of these
enzymes can help us understand human counterparts of GTs,
and provide a convenient technology to synthesize both bacter-
ial and human glycans. Bacterial GTs can be easily expressed and
stored; they are more soluble and often remarkably active and
stable.
Currently, GTs from many different organisms have been clas-
sified into 96 GT families in the Carbohydrate-active Enzymes
(CAZy) classification system (http://www.cazy.org), based on their
sequence similarity derived from GenBank (ftp://ftp.ncbi.nih.gov/
genbank/ or EMBL or DDBJ) (1, 2). Very few of the bacterial
GTs have been biochemically and functionally characterized, thus
proposed enzymes are assigned based on similarity searches. The
CAZy database also contains genetic, structural, mechanistic, and
functional information of known GTs. The former Escherichia
coli (EC) nomenclature for GTs as well as the currently accepted
nomenclature and alternative names for GTs are included. A num-
ber of databases provide sequence analyses of GTs (e.g., NCBI
BLAST, PFAM, INTERPRO, DBCAN, Swiss-Prot – ExPASy).
For searches of glycan structures, a number of databases
are useful (3). For example, GLYCOSuiteDB contains informa-
tion on N- and O-linked glycans and glycoproteins and Gly-
cobase on N- and O-Glycan structures. For glycomics analyses by
mass spectrometry (MS), GlycoMaster DB at http://www-novo.
cs.uwaterloo.ca:8080/GlycoMasterDB is helpful (4). The current
E. coli O-antigen database (ECODAB) contains known O antigen
structures of E. coli, the analytic data available, and has links to
genes involved in O antigen synthesis from the O antigen gene
cluster (5). Many of the E. coli antigens can be found in other bac-
terial strains. Finally, the Consortium for Functional Glycomics
(http://www.functionalglycomics.org/) provides a large database
for glycan functions.
Because of wide-spread development of antibiotic resistance,
we need new anti-bacterial strategies, and bacterial GTs are vir-
ulence factors that could be targeted. The understanding of GTs
can help in the production of vaccines to protect against bacte-
rial infections, cancer, and for application in inflammation and
autoimmune disease. In this review, we will compare mammalian
and bacterial GTs that show remarkable similarity of action,
protein folding, or mechanisms, in spite of surprisingly large
differences in amino acid sequences.
MAMMALIAN GLYCOPROTEINS AND BACTERIAL GLYCANS
Mammalian glycoproteins are involved in virtually all cellular
activities; they serve as ligands for antibodies or lectins, or as
receptors involved in signaling, cellular interactions, cell growth,
differentiation, and cell death (6–11). Glycans are important in the
inflammatory response, the innate and adaptive immune system,
and cancer metastasis, as well as microbial colonization and infec-
tions. Glycoproteins have many functional epitopes attached to
either N-glycans or O-glycans, and the amounts of many of these
epitopes can be altered in disease, for example, in cancer. Although
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there is remarkable diversity in glycan structures in mammals, and
hundreds of different chains can be found in glycoproteins, only
six sugar residues (Man, GlcNAc, GalNAc, Gal, sialic acid, Fuc)
are forming the extended and branched varieties of glycans with
few modifications such as O-acetylation and sulfation. N- and
O-glycans can affect the chemical and physical properties and the
conformations of proteins and the accessibility of peptide epitopes.
Bacteria display an astounding variety of unusual sugars and
sugar linkages as well as modifications of sugars that are foreign to
human beings and, therefore, can trigger immune responses. How-
ever, a number of specific bacterial glycans are mimics of mam-
malian glycoprotein epitopes (Table 1). Partial structures of O-
antigenic polysaccharides of Gram-negative bacteria (ECODAB)
often mimic human glycans and may help bacteria to evade the
immune system and promote colonization. The mimicry may
prevent the production of effective vaccines to protect against
bacterial infections, which requires new considerations of anti-
bacterial strategies. About half of the EC strains have some form of
mammalian epitope within their O antigens. This includes Galβ1-
3GlcNAcβ-, and Galβ1-4GlcNAcβ-linkages, which are part of the
glycan backbone structures (type 1 and type 2, respectively) in
mammalian glycoproteins. In bacteria, those are internal struc-
tures within the O antigen repeating unit. The cancer-associated
Thomsen–Friedenreich (TF or T antigen, O-glycan core 1) is com-
mon in glycoproteins and also found in several O antigens of
E. coli. Blood group O, A, and B, sialylated glycans, and poly-
sialic acid are mimics found in a number of bacterial strains. The
fact that bacteria are able to synthesize these human-like struc-
tures suggests that they have the appropriate biosynthetic enzymes
(Table 2), although this would be difficult to anticipate from the
inspection of the amino acid sequences of their GTs. Biochemi-
cal characterization of bacterial enzymes and structure/function
studies are important prerequisites to utilize these enzymes in
chemoenzymatic synthesis of mammalian glycoprotein epitope
structures.
ROLE OF O ANTIGENS
The LPS of Gram-negative bacteria are essential structures of the
outer membrane. LPS binds to the LPS-binding protein, requir-
ing the CD14/TLR4/MD2 receptor complex, which elicits a strong
response during infections, through TLR4 signaling. LPS consist
of a lipid A base (endotoxin), which carries a relatively invariable
inner oligosaccharide core, strain-specific outer core oligosaccha-
rides, and the serotype-specific outer O antigen polysaccharide.
O antigens are polysaccharides composed of up to 50 repeating
units of oligosaccharides with one (homopolymeric) to 10 sug-
ars (heteropolymeric) that play a role in bacterial adhesion and
colonization, affect pathogenicity and survival, and can be bac-
teriophage receptors. The enormous structural variability of O
antigens is mediated by many specific GTs and other enzymes
that modify O antigens, thus increasing structural diversity, e.g.,
by adding phosphate, acetyl groups, or branching sugar residues.
The LPS molecules are necessary for stabilization of the outer
membrane and form a barrier against penetration of toxins. In
particular, the O antigens serve to evade complement; they pro-
tect against phagocytosis and give the bacteria a strain-specific
and diversity-selective advantage. The molecular mimicry found
Table 1 | Glycan mimics: examples of mammalian glycoprotein
epitopes also found in the lipopolysaccharides (LPS) or
lipooligosaccharides of Gram-negative bacteria.
Glycoprotein
epitope
Structure Bacteria
T antigen Galβ1–3GalNAcα- EC O104, EC
O5, EC 0127
Sialyl-T antigen Sialylα2–3Galβ1–3GalNAcα- EC O104
Type 1 chain Galβ1–3GlcNAc- EC O7, EC O55
Type 2 chain Galβ1–4GlcNAc- EC O91
Lewis a Fucα1–4[Galβ1–3]GlcNAcβ- Hp
Lewis b Fucα1–4[Fucα1–2Galβ1–3]GlcNAcβ- Hp
Lewis x Galβ1–4[Fucα1–3]GlcNAcβ- Hp
Lewis y Fucα1–2Galβ1–4[Fucα1–3]GlcNAcβ- Hp
H antigen Fucα1–2Galβ- EC O86
Blood group A GalNAcα1–3[Fucα1–2]Galβ- Bo
Blood group B Galα1–3[Fucα1–2]Galβ- EC O86
Linear B Galα1–3Galβ- Nm
P blood group Galα1–4Galβ- Cj, Nm
Polysialic acids, PSA [Sialylα2–8]n EC, Nm
Sialylα2-3 Sialylα2–3Galβ- Cj, EC O104
Sialylα2-6 Sialylα2–6Galβ- Psp
Fucα1-6 Fucα1–6GlcNAcβ- Rsp
Bo, Bacteroides ovatus; Cj, Campylobacter jejuni; EC, Escherichia coli; Hp, Heli-
cobacter pylori; Nm, Neisseria meningitides; Psp, Photobacterium sp.; Rsp,
Rhizobium sp.
in a large proportion of bacteria adds to their ability to pre-
vent recognition by the host immune system and thus promotes
virulence.
A number of bacteria do not have an extended O-antigenic
polysaccharide but instead have a short lipooligosaccharide that
may have structural identity with human glycoproteins or gly-
colipids and may lead to pathological conditions. The close
relationship between bacteria and human beings is also appar-
ent in the abundance of bacterial lectins that bind to mam-
malian glycoproteins and thus promote adhesion to mammalian
tissues.
N-GLYCOSYLATION OFMAMMALIAN AND BACTERIAL GLYCOPROTEINS
In eukaryotic cells, N-glycans are assembled first on a dolichol-
phosphate (P-Dol) intermediate on the cytoplasmic side of
the endoplasmic reticulum (ER) membrane (7, 12) (Figure 1).
GlcNAc-phosphate is transferred by GlcNAc-phosphotransferase
in a reversible reaction, inhibited by tunicamycin, to P-Dol, fol-
lowed by the transfer of another GlcNAc residue to form chito-
biose. This is followed by five Man residues, all transferred from
nucleotide sugar donor substrates to form the common N-glycan
core structure Man5-chitobiose linked to PP-Dol. This heptasac-
charide is flipped across the membrane and further addition of
sugars occurs on the inside of the ER lumen through transfer
from Man-P-Dol and Glc-P-Dol donor substrates. After comple-
tion of the lipid-linked N-glycan, it is transferred en bloc to the
Asn residue(s) of Asn-X-Ser/Thr sequons in a glycoprotein by
the oligosaccharyltransferase complex (OST), and Glc and Man
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Table 2 | Comparison of characterized mammalian and bacterial enzymes that catalyze a similar reaction.
Human enzyme
(Accession No.)
Acceptor Bacterial enzyme
(Species) (Accession No.)
Acceptor Identity
Core 1 β3-Gal-transferase, C1GALT1,
T synthase (NP_064541, Q9NS00)
GalNAcα- WbwC (ECO104) (AAK64375, Q93NP5) GalNAcα-PP-lipid 10.5
WbiP (ECO127) (YP_002329684, B7UT68) GalNAcα-R 10.6
CgtB (Cj ) (ABL75151, A2I3T3) GalNAcβ-R 8.4
β4-Gal-transferase 1, B4GALT1 (P15291) GlcNAcβ- LgtB (Nm) (EJU76624, J8YER7) GlcNAcβ-R 9.3
WfeD (Sb) (ACD37055, B5L3X1) GlcNAcα-PP-R 8.6
β3-Gal-transferase 5, B3GALT5
(NP_149361, Q9Y2C3)
GlcNAcβ- WbgO (ECO55) (ADD57106, D3QY14) GlcNAcβ-R 11.4
WbbD (ECO7) (AAC27537, Q03084) GlcNAcα-PP-lipid 13
β3-GlcNAc-transferase 2, B3GNT2
(AAD09764, Q9NY97)
Galβ- LgtA (Nm) (AAL12840, Q93EK6) lactose 11.6
α3-Gal-transferase, ABO transferase GTB
(AAD26574, Q9UQ64)
Fucα2Galβ- WbnI (ECO86) (AAV80756, Q5JBG6) Fucα2Galβ-R 20.6
α4-Gal-transferase, A4GALT (AAO39150,
Q540I6)
Galβ- CgtD (Cj) (AAM90647, Q8KWQ9) Galβ-R 11.6
LgtC (Nm) (AAL12839, Q93EK7) Galβ-R 10.7
α3-GalNAc-transferase, ABO transferase
GTA (V5ZDN8, P16442)
Fucα2Galβ- BoGT56a (Bo) (4AYL_A, A7LVT2) Fucα2Galβ-R 21.1
GTA-like (Hm) (CBG40459, D3UIY4) Fucα2Galβ-R 19.7
α3-Sialyl-transferase ST3GAL1
(NP_775479, Q11201)
Galβ3GalNAc- NST (Nm) (C6S6J1) Lactoseβ-benzyl 13.2
WbwA (ECO104) (AAK64371, Q93NP9) Galβ3GalNAcα-PP-lipid 13.6
α3-Sialyl-transferase, ST3GAL4 (Q11206) Galβ3- CstI (Cj ) (ADA70348, D2KQ02) Galβ3-R 10.2
α6-Sialyl-transferase, ST6GAL1 (P15907) Galβ3- Pm0188 (Pm) (Q9CP67) Galβ-R 14.6
α6Sialyltransferase (Psp) (A8QYL1) Galβ-R 14.6
Poly α8-sialyl-transferase 2, ST8SIA2
(AAH10645, Q92186)
sialyl-Gal- PST (Nm) (AAS90326, Q6PUE5) GD1 ganglioside 9.8
PST (EC ) (B1LEB7) Sialyl-R 5.4
α2-Fuc-transferase, FUT2 (CAQ81982,
A8K2L2)
Galβ- WbwK (ECO86) (AAO37719, Q5JBG3) Galβ3GalNAc- 11.9
WbsJ (ECO128) (AAO37698, Q6XQ53) Galβ4-R 15.8
FutC (Hp) (ABO61750, A4L7J1) Galβ- 17.5
α3-Fuc-transferase, FUT4 (NP_002024,
P22083)
Galβ4GlcNAcβ- FutA (Hp) (YP_003057735, C7BXF2) Galβ4GlcNAcβ-R 10
FutB (Hp) (YP_003057467, C7BZU7) Galβ4GlcNAcβ-R 10.2
α3FUT (Hh) (Q7VFA1) (Sialyl-)Galβ4GlcNAcβ-R 10.4
α3/4-Fuc-transferase, FUT3 (P21217) Galβ4/3GlcNAcβ- FucTa (Hp) (AAF35291, Q9L8S4) Galβ4/3GlcNAcβ-R 14.5
α6-Fuc-transferase, FUT8 (AAI42959,
A5PLL2)
N-glycan core NodZ (Rsp) (G9ACH1) Chitobiose 7.6
The donor substrates of mammalian and bacterial enzymes that synthesize the same linkage are the same but the preferred acceptor substrate may differ. The
bacterial enzyme can mimic the mammalian enzyme and can be used to synthesize mammalian glycan structures but the amino acid sequences have little sequence
identities. The percentage of amino acid identity is much higher among eukaryotic GT families and between GTs with similar action and using similar acceptors in
bacteria.The accession numbers in bold (Accession No.) are from Pubmed and/or UniProt database. Bo, Bacteroides ovatus; Cj, Campylobacter jejuni; EC, E. coli; Hh,
Helicobacter hepaticus; Hm, Helicobacter mustelae; Hp, Helicobacter pylori; Nm, Neisseria meningitides; Pm, Pasteurella multocida; Psp, Photobacterium sp.; Rsp,
Rhizobium sp.; Sb, Shigella boydii; PP-, diphosphate-.
residues are selectively cleaved by glycosidases. After transfer to
the Golgi, further removal of Man residues occurs, and GlcNAc-
transferase I (GnT I, MGAT1) adds the first of the N-glycan anten-
nae in β1–2 linkage to the Manα1–3 arm of the core. This can then
be followed by several steps that depend on the presence of this
first GlcNAc antenna and the expression of processing enzymes,
which remove two Man residues from the Manα1–6 arm, add
Fucα1–6 to the inner chitobiose GlcNAc, and add further anten-
nae to form complex type N-glycans. N-glycans can be extended
by repeating Gal-GlcNAc residues to form type 1 or type 2 chains
(Table 1); they may be branched by GlcNAcβ1–6 linkages and may
be decorated with specific functional epitopes and blood group
determinants (7). This results in hundreds of different N-glycan
structures, depending on the glycosylation potential of the cell.
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FIGURE 1 | Biosynthesis of N-glycosylated glycoproteins in eukaryotes.
N-glycosylation is initiated at the endoplasmic reticulum (ER) membrane using
nucleotide sugar donor substrates and a membrane-bound acceptor
phospholipid with multiple isoprenyl units (dolichol-phosphate, P-Dol). The first
sugar (GlcNAc) is transferred as GlcNAc-phosphate from UDP-GlcNAc by
GlcNAc-P-transferase, resulting in GlcNAc-diphosphate-dolichol
(GlcNAc-PP-Dol). This step can be inhibited by the UDP-GlcNAc analog
tunicamycin. On the outside face of the ER membrane, another GlcNAc is
added to form chitobiose, followed by five Man residues to form a
heptasaccharide (Man5GlcNAc2)-PP-Dol. This heptasaccharide is flipped to the
inside of the ER where the chain grows by transfer of sugars from
membrane-bound Man-P-Dol and Glc-P-Dol. The completed saccharide
Glc3Man9GlcNAc2 is then transferred by an oligosaccharyltransferase complex
(OST) to the Asn residue in an Asn-x-Ser/Thr sequon of nascent proteins. After
trimming of sugar residues in the ER by removal of Glc and Man residues to
the Man8GlcNAc2 structure, glycoproteins are exported to the Golgi where
further trimming occurs by mannosidases. Many N-glycan chains are
processed to the complex type by the addition of GlcNAc residues by
GlcNAc-transferases I to V (MGAT1 to 5). Chains grow further by the addition
of Gal-GlcNAc sequences and termination by sialyl-, Fuc-, Gal-, GlcNAc-, and
GalNAc-transferases, which are all highly specific for both the donor and the
acceptor substrates and with few exceptions form only one type of linkage
between sugars. This creates a multitude of hundreds of different structures
and epitopes with many possible functions, depending on the final destination
of the glycoprotein, e.g., in the cell membrane or in secretions. Glycoprotein
biosynthesis is regulated at many different levels, e.g., by the synthesis and
delivery of nucleotide sugar substrates, the expression, activities and
localization of glycosyltransferases and trimming hydrolases, the competition
of enzymes for common substrates, levels of metal ion activating factors,
localization of enzymes involved, and rate of transport of glycoproteins.
Not all N-glycosylation sites carry N-glycans, and there are dif-
ferences in chain processing between different glycosylation sites
of the same protein. The peptide has been shown to interact with
the glycan chains, and this controls the conformations of the gly-
can and the peptide and leads to site-specific glycosylation. Many
sequentially acting and competing GTs assemble glycoproteins in
a cell type-specific pattern. Most of the GTs involved exist as fam-
ilies of enzymes (Table 3). Several of these have been shown to be
localized in specific Golgi compartments according to their action
within the complex pathways.
In the mammalian biosynthetic pathways, the sequence of sugar
additions is controlled by the gene expression, the relative activ-
ities of competing enzymes, the enzyme localizations, levels of
substrates and cofactors, and the distinct substrate specificities
of GTs. These types of controls still need to be investigated for
glycosylation reactions in bacteria.
Bacteria such as Campylobacter jejuni (Cj) also have N-
glycosylated proteins (13). An oligosaccharide is first assembled
on undecaprenol-phosphate (P-Und), an analog of P-Dol, in the
cytoplasmic compartment. The sugar-PP-Und is then flipped to
the periplasmic space where the glycan chain is transferred en bloc
to protein by oligosaccharyltransferases. These GTs have a broad
specificity toward their donor substrates but also require a sequon,
Asp/Glu–x–Asn–y-Ser/Thr, where x and y cannot be Pro, in the
protein acceptor, that bears close resemblance to the mammalian
N-glycosylation sequon (Figure 1).
PROTEIN O-GLYCOSYLATION
O-glycans of glycoproteins and mucins are assembled in mam-
mals without a lipid intermediate and without removal of sugar
residues by glycosidases (14,15). The first sugar is always GalNAcα-
linked to Ser or Thr (the cancer-associated Tn antigen). All sugars
are transferred from nucleotide sugars in the Golgi, resulting in
extended and branched O-glycans with hundreds of different
structures. The most common structure is Galβ1-3GalNAc, core 1,
the T antigen, which is normally masked by the addition of other
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Table 3 | Examples of glycosyltransferase families (CAZy).
GT
family
Mechanism Fold Glycosyltransferases Known
structures
2 I GT-A WbbD, WbwC, WbiP, CgtB,
WbgO, WfaP, WfgD, LgtA
7
6 R GT-A GTA, GTB, A3GALT, WbnI,
BoGT56a, GTA-like (Hm)
4
7 I GT-A B4GALT 4
8 R GT-A LgtC 5
10 I GT-B α3/4FUT, FutA, FutB, FucTa,
FUT3, FUT4-7, 9-11
1
11 I GT-B α2FUT, α3FUT (Hh), WbwK,
Wbsj, FutC
–
13 I GT-A GnT I, MGAT1 1
14 I GT-A C2GnT1, IGnT, GCNT2 1
16 I ? MGAT2 –
17 I ? MGAT3 –
18 I ? MGAT5 –
23 I GT-B α6FUT8, NodZ 2
25 I ? LgtB –
26 I ? WfeD –
27 R GT-A GALNT 3
29 I GT-A Animal sialyl-T, ST3GAL,
ST6GAL, ST6GALNAC,
ST8SIA
3
31 I GT-A C1GALT, B3GALT5 1
32 R ? CgtD, Lgt5, A4GALT –
38 I ? Bacterial PST –
42 I GT-A Bacterial Sialyl-T, CstI, CstII 2
52 I GT-B Bacterial Sialyl-T, NST, WbwA 1
54 I ? MGAT4 –
80 I GT-B Bacterial Sialyl-T, Pm0188,
α6Sialyl-T (Psp), PmST1,
multifunctional
4
Fold, expected overall fold; Hh, Helicobacter hepaticus; Hm, Helicobacter muste-
lae; I, Inverting mechanism; Psp, Photobacterium sp.; R, Retaining mechanism;
-T, -transferase.
residues but exposed in many cancer cells. In a number of cells,
core 1 is branched by core 2 β6-GlcNAc-transferase (C2GnT) or
extended in a fashion that is similar to the synthesis of complex
N-glycans.
GalNAc is transferred from UDP-GalNAc by up to 20 polypep-
tide GalNAc-transferases (GALNTs) (14–16). All GALNTs are
classified in the GT27 family with a GT-A fold (Table 3). They
have a catalytic domain linked to a lectin (ricin-like) domain at
the C terminus. This lectin domain has three subdomains and
may play an important role in binding products or substrates con-
taining GalNAc residues. A crystal structure of mouse GALNT1
with Mn2+ supported the importance of a DxH motif and the
role of Asp209, His211, and His344 (17) (Table 4). The confor-
mations of human GALNT2 (18) crystallized with UDP and with
or without an acceptor peptide showed a loop formed over UDP.
It appeared that the acceptor peptide connected the otherwise
separate catalytic and lectin domains. Kinetic analyses showed
that the presence of GalNAc in the acceptor was beneficial for
activity. Human GALNT10 was crystallized complexed with UDP,
GalNAc, and Mn2+ (19). GalNAc-peptides appear to bind to the
second beta-subdomain of the lectin domain. Binding of the donor
induces a conformation change that opens the acceptor-binding
site. These three crystallized ppGalNAcTs are similar in overall
structure and mechanism.
An equivalent GALNT that transfers GalNAc to protein has
not been identified in bacteria, although bacteria are known to
O-glycosylate Ser/Thr residues of proteins with various sugar
residues. In contrast to mammalian O-glycosylation, bacteria
transfer a pre-assembled oligosaccharide to Ser/Thr. Bacterial pro-
tein OGTs have no sequence homology to GALNT and their action
is reminiscent to that of OST in the N-glycosylation pathway. In
several bacteria, for example in Campylobacter and Neissseria, an
oligosaccharide or monosaccharide is first pre-assembled on PP-
lipid in the cytoplasmic compartment, flipped to the periplasm
and then transferred en bloc to Ser/Thr residues of proteins. These
enzymes have a relaxed oligosaccharide donor specificity (46).
Oligosaccharyltransferase PglL (which has not yet been assigned to
a GT family) from Neisseria meningitides (Nm) can transfer many
different glycans from sugar-PP-Und or sugar-PP-lipid (includ-
ing sugar-PP-Dol) donor substrates to protein in the periplasmic
space. UDP-N -diacetyl-bacillosamine was also a donor substrate
in vitro, showing that even nucleotide sugars can be donors and a
single sugar could be transferred to protein. Mutagenesis experi-
ments showed that PglL from Nm requires His349 for activity and
for interaction with the lipid-linked oligosaccharide (47).
BIOSYNTHESIS OF BACTERIAL O ANTIGENS
There are many similarities in the pathways and mechanisms by
which bacterial O antigens and mammalian glycoproteins are
synthesized. In Gram-negative bacteria, O antigens are synthe-
sized by specific GTs at the cytosolic face of the inner mem-
brane where the nucleotide sugar donor substrates are present,
as well as the membrane-bound P-Und, an analog of the mam-
malian P-Dol, as the acceptor substrate for the transfer of the
first sugar (48) (Figure 2). The first GT to act is always a sugar-
phosphate transferase that produces the sugar-PP-Und substrate
for subsequent transfer of monosaccharides by GTs. Most E. coli
have GlcNAc or GalNAc at the reducing end of the repeating
unit, thus sugar-phosphate transferase WecA and its orthologs
are responsible for the first reaction, maintaining the α-anomeric
configuration of GlcNAc. 4-Epimerases may also be involved
in interconverting GlcNAc and GalNAc in the activated form
(UDP-GlcNAc/UDP-GalNAc) or after the sugar transfer (49).
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Table 4 | Mammalian and bacterial glycosyltransferases with known crystal structure relevant to glycoprotein determinants or their mimics.
Enzyme name Species Donor Acceptor GT Fold DxD Reference
INVERTING
GnT I, MGAT1 Rabbit UDP-GlcNAc Manα3-R 13 GT-A DxD (19)
C2GnT, GCNT1 Mouse UDP-GlcNAc Galβ3GalNAc-R 14 GT-A E320 (20, 21)
β4-Gal-T1, B4GALT1 Human UDP-Gal GlcNAcβ-R 7 GT-A DxD (22)
β4-Gal-T1, B4GALT1 Bovine UDP-Gal GlcNAcβ-R 7 GT-A DxD (23)
β4-Gal-T7, B4GALT7 Human UDP-Gal GlcNAcβ-R 7 GT-A DxD (24)
α3-FUT Hp GDP-Fuc Galβ4GlcNAc 10 GT-B E95, E249 (25)
α6-FUT8 Human GDP-Fuc N-glycan core Gn 23 GT-B D453 (26)
NodZ Rsp GDP-Fuc chitobiose 23 GT-B (27)
ST3GAL1 Pig CMP-SA Galβ3GalNAc-R 29 GT-A H319 (28)
α3-Sialyl-T Pp CMP-SA Gal-R 80 GT-B H317 (29)
α3-Sialyl-T CstI Cj CMP-SA Galβ-R 42 GT-A H202 (30)
α3-Sialyl-T NST Nm CMP-SA Lactose-Bn 52 GT-A H280 (31)
ST6GAL1 Rat CMP-SA Galβ4GlcNAc 29 GT-A H367 (32)
ST6GAL1 Human CMP-SA Galβ4GlcNAc 29 GT-A H370 (33)
α6-Sialyl-T PM0188 Pm CMP-SA Lactose, Gal, GalNAc, SA 80 GT-B D141 (34)
α6-Sialyl-T pst6-224 Psp CMP-SA Lactose 80 GT-B (35)
α3/8-Sialyl-T CstII Cj CMP-SA Galβ-R 42 GT-A H188 (36)
α3-Sialyl-T multi PmST1 Pm CMP-SA Lactose, Gal, GalNAc, sialic acid 80 GT-B D141 (37)
RETAINING
GALNT1 Mouse UDP-GalNAc Thr/Ser 27 GT-A-ricin (17)
GALNT2 Human UDP-GalNAc Thr/Ser 27 GT-A-ricin (18)
GALNT10 Human UDP-GalNAc Thr/Ser 27 GT-A-ricin (38)
ABO transferase GTB Human UDP-Gal H antigen 6 GT-A E303 (39)
H347 (40)
α3-Gal-T Linear B Bovine UDP-Gal Galβ4GlcNAc 6 GT-A E317, H271 (41, 42)
Gal-T
ABO transferase GTA Human UDP-GalNAc H antigen 6 GT-A E303 (39, 43)
H347
α3-GalNAc-T BoGT6a Bo UDP-GalNAc Fuc-lactose 6 GT-A NxN (44)
α4-Gal-T LgtC Nm UDP-Gal Lactose, oligosac 8 GT-B 4DxD, H188 (45)
Enzymes are listed that have been characterized and crystallized and shown to be involved in the synthesis of glycoproteins or their glycan mimics in bacteria. Bo,
Bacteroides ovatus; Bs, bacillus subtilis; Cj, Campylobacter jejuni; DxD, presence of a DxD motif or its analog or proposed catalytic residue; GT, Glycosyltransferase
family (CAZy); Hp, Helicobacter pylori; multi, multifunctional enzyme; Inverting: enzymes invert the anomeric configuration of the sugar of the donor substrate to form
enzyme product; N-glycan core Gn, reducing GlcNAc residue of the N-glycan core structure; Nm, Neisseria meningitides; Pm, Pasteurella multocida; Pp, Photobac-
terium phosphoreum; Psp, Photobacterium sp.; Rsp, Rhizobium sp.; Retaining: enzymes retain the anomeric configuration of the sugar of the donor substrate in the
enzyme product; SA, sialic acid; -T, -transferase.
The common heteropolymeric O antigens are synthesized by
sequential transfer of sugar units by donor- and acceptor-specific,
membrane-associated GTs. The specificities of these bacterial GTs
are distinct and comparable to eukaryotic GTs. A completed
repeating unit is then translocated across the inner membrane to
the periplasmic side by the multiple membrane-spanning flippase
Wzx, a process resembling the transfer of Man5GlcNAc2–PP-Dol
intermediate across the ER membrane. Polymerization involves
the addition of repeating units to the reducing end of the growing
chain by Wzy polymerase. This enzyme has 12 predicted trans-
membrane domains with the catalytic domain in the periplasm
that has some specificity for the structure of the repeating unit.
Wzy may invert the anomeric linkage of the first sugar in the poly-
saccharide since many repeating units have the GlcNAcβ-linkage
in the O antigen. Many genes specifically involved in the synthesis
of the O antigen are found in the O antigen gene cluster. The pres-
ence of the wzy gene suggests that the O antigen is synthesized
by the Wzy-dependent pathway (Figure 2). A much less specific
chain terminator Wzz then helps to restrict the number of repeat-
ing units assembled in the O antigen. This is followed by a ligase
(polysaccharide transferase)-catalyzed transfer of the O antigen to
a specific sugar of the outer core structure, synthesizing the com-
plete LPS. This releases PP-Und, which is recycled to P-Und. LPS
is then extruded to the outer membrane by the Lpt complex (50).
The less common homopolymeric O antigens, such as the d-
Rha polymers of Pseudomonas aeruginosa (Pa) and the d-Man
polymers of E. coli O9, are synthesized by the transfer of mono-
saccharides from nucleotide sugars to R-GlcNAc-PP-Und in a
processive fashion in the ABC transporter-dependent pathway
(Figure 3) (51). Some of the processive GTs can have multiple
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FIGURE 2 | Biosynthesis of lipopolysaccharides in Gram-negative
bacteria by the polymerase-dependent pathway. Many steps of the
complex sequences and controls in the biosynthesis of LPS in
Gram-negative bacteria are similar to those in mammalian glycoprotein
biosynthesis. The inner membrane serves as the site of glycan biosynthesis,
and the membrane-bound acceptor is undecaprenol-phosphate (P-Und)
having 11 isoprenyl units, which is less than those found in eukaryotic Dol.
Nucleotide sugars are synthesized in the cytosol and used for most
glycosylation reactions. As in the N-glycan biosynthesis, the first sugar is
transferred as sugar-phosphate by membrane-bound WecA to synthesize
GalNAc/GlcNAc-PP-Und. This step can also be blocked by tunicamycin. It is
possible that a 4-epimerase is involved. Subsequently, sugars are added
individually to form the repeating unit of the O antigen. The
glycosyltransferases that transfer sugars from nucleotide sugars usually
have a high specificity for their donor and acceptor substrates and are
associated with the membrane. After Wzx transports the repeating units to
the periplasm, they are polymerized by Wzy by addition of repeating units to
the reducing end of the growing polysaccharide linked to PP-Dol. The O
antigen can be further processed and modified to form completed O
antigens and the biosynthesis is usually terminated with Wzz. The O
polysaccharide is then transferred to a sugar of the core oligosaccharide
linked to lipid A by a ligase, forming the LPS, which is exported to the outer
membrane by the Lpt complex. The O antigenic polysaccharide is then
exposed to the environment on the outer membrane. Although many
bacterial enzymes involved in LPS synthesis have been cloned, the
individual steps of LPS synthesis are not well understood, mainly because
of the major challenge to find the appropriate enzyme substrates and
conditions to assay enzymes. The example shows the biosynthesis of the E.
coli O104 antigen. The repeating unit tetrasaccharide contains the
cancer-associated T antigen (Galβ1-3GalNAc), as well as the sialyl-T antigen
(sialylα2-3Galβ1-3GalNAc). The WbwA sialyltransferase and the WbwB
Gal-transferase remain to be characterized.
catalytic domains, e.g., Man-transferase WbdA. The entire O anti-
gen is assembled on the cytosolic side, and terminated by termina-
tion reactions, e.g., methylation. This is followed by translocation
of the large O-antigen-PP-Und by the Wzm exporter and the ATP-
binding Wzt to the periplasm where it is further processed. The
presence of wzm and wzt genes in the O antigen gene cluster would
suggest that this pathway is operative.
The events utilizing membrane-bound acceptor substrates in
bacteria are similar to those of the early N-glycan synthesis in
eukaryotes at the ER inner membrane (Figure 1). In both mam-
mals and bacteria, isoenzymes are known that can synthesize the
same linkage, often with slightly different substrate specificity.
These isoenzymes are interesting models to study the catalytic
sites and requirement for specific amino acids critical for catalysis
and specificity.
CHARACTERIZATION OF GLYCOSYLTRANSFERASES
Chemical synthesis has been used to produce natural-like or
unnatural glycans but the stereochemistry and regio-selectivity
is difficult to achieve. Nature has developed GTs, excellent tools
to synthesize an amazing diversity of glycan structures with
defined anomeric configurations and linkages. GT reactions do
not require harsh conditions or protection of reactive groups.
GTs have distinct specificities for their donor and acceptor sub-
strates. More than 100,000 genes from various species are thought
to encode GTs, and organisms have 1–2% of their genes dedicated
to GTs (52).
In order to assess the requirements and characteristics of GT
activities, specific and accurate enzyme assays have to be devel-
oped. Nucleotide sugar donor substrates for mammalian glyco-
protein biosynthesis are usually commercially available but for
bacterial enzymes may have to be chemically or enzymatically
synthesized. It would be difficult to extract the natural donor and
acceptor substrates from bacteria in the pure form. Therefore,
syntheses for bacteria-specific donor substrate analogs have been
developed, e.g., for UDP-QuiNAc (UDP-6-deoxy-GlcNAc) found
in E. coli and Pseudomonas aeruginosan (PA) (53) or for GDP-
d-Rha found in PA (54). Oligosaccharides linked to a synthetic
aglycone group may be suitable acceptors for both, mammalian
GTs and bacterial GTs. However, bacterial GTs that act early in the
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FIGURE 3 | Biosynthesis of polysialic acids in E. coli using the ABC
transporter pathway. The biosynthesis of homopolymeric O antigens (or
capsules) is initiated at the cytosolic side of the inner membrane. Polysialic
acids (PSA) of E. coli are proposed to be assembled in a processive fashion as
shown, based on undecaprenol-phosphate. Membrane-associated
polysialyltransferase (PST) transfers many units of sialic acid from CMP-sialic
acid to the growing polysialic acid. The enzyme can act on a number of
acceptor substrates to form repeated sialylα2–8 linkages. A termination
reaction stops the growth of the long PSA chain. The PSA is then transported
to the periplasmic space by the Wzm exporter, which is associated with the
ATP-binding Wzt. Further processing occurs in the periplasm. The completed
PSA is ligated to the core-lipid A and then translocated by export proteins to
the outer membrane to serve as a highly charged and hydrophilic protective
coat. Other homopolymeric O antigens such as poly-D-Mannose or
poly-D-Rhamnose are processed in a similar fashion by the ABC transporter
pathway.
O antigen synthesis pathway seem to require sugar-diphosphate-
lipids as acceptors, which are difficult to synthesize. We developed
the natural acceptor analog GlcNAcα-diphosphate-lipid to mimic
the product of the first sugar-phosphate addition (55), which
was very active as an acceptor. In order to isolate the enzyme
product from the assay mixture for quantification, a number of
different chromatographic methods have been employed, includ-
ing hydrophobic or anion exchange methods, HPLC, TLC, and
capillary electrophoresis. Enzyme-coupled assays or lectin and
antibody binding have also been used to determine activities.
Methods to assay specific GTs are essential prerequisites to study
their properties and optimal conditions, substrate specificities, and
to develop inhibitors.
GTs can be classified based on similarities of their amino acid
sequences, according to the sugar they transfer, and the stereo-
chemistry of the reaction in the CAZy database. If at least 100
amino acids in two different stretches of the protein have signif-
icant similarity to other members of the same family but not to
other families, GTs are assigned to a specific family with the same
predicted fold, and being either inverting or retaining GT (Tables 3
and 4). However, not all known sequences fit into a GT family or
are reclassified when the specific function of the GT has been
established, and the number of families are growing. Sequence
similarity of unknown proteins can be used to predict function
and protein folding. However, the final proof of function has to be
obtained by biochemical analysis of enzymes. Most GTs in bacte-
ria have not been functionally characterized, and this area is both
challenging and tedious, often because the appropriate donor and
acceptor substrates have to be especially prepared.
Crystal structures for GTs from eukaryotic and prokaryotic
sources have been helpful in delineating the catalytic actions of
GTs. It is interesting that this large and important class of thou-
sands of enzymes that bind to many different nucleotide sugars
as well as to a very large variety of monosaccharides, oligosac-
charides, glycopeptides, and glycolipids occurs in only two major
fold types, GT-A and GT-B. GTs, thus, have a relatively con-
served three-dimensional architecture within their catalytic sites
and share mechanisms, resulting in an extremely large number
of product structures with linear or branched glycans of mostly
unknown functions.
The binding of substrates to GTs and the transfer reactions
have been shown to involve conformational changes in the enzyme
proteins. GT-A folded enzymes have two tightly associated α/βα
Rossman nucleotide-binding-like domains with two α-helices sur-
rounding an open twisted, central β-sheet. The donor and acceptor
substrates bind in different domains. The GT-B folded enzymes
have two β/α/β Rossman-like domains, which are less tightly asso-
ciated with each other and have the active site in the cleft in
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between domains (56). Usually, the sugar donor substrate binds
first. This induces a conformational change in the enzyme form-
ing a lid over the nucleotide sugar, facilitating the binding of
the acceptor substrate and catalysis in an ordered sequential,
regio- and stereo-specific mechanism (57, 58). Internal disordered
loops seem to be a common feature in mammalian and bacterial
enzymes (40). Upon substrate binding, a disordered, short protein
loop becomes ordered when donor substrate is bound. A change
in orientation and conformation of the resulting ordered loop
appears to facilitate binding of the second substrate and catalysis.
Thus, the function of an ordered loop could be to allow cataly-
sis, possibly by excluding water that would hydrolyze the donor
substrate, or to form a lid over the nucleotide binding site allow-
ing acceptor to bind, or to allow movement, and facilitating the
reaction.
Generally, GTs have a distinct acceptor substrate specificity and
with few exceptions, utilize only one type of nucleotide sugar
donor substrate. Although few of the bacterial GTs have been
biochemically characterized, it appears that both bacterial and
mammalian GTs generally have similar properties with respect
to their optimal pH, metal ion requirement, and donor specificity,
although some bacterial GTs have a more promiscuous acceptor
specificity (59). They can, thus, synthesize unnatural linkages that
may find application as inhibitors or for biological studies. For
example, β4-Gal-transferase LgtB from Helicobacter pylori (Hp)
has been used to synthesize thio-glycosides.
A comparison of mammalian and corresponding bacterial GTs
(Table 2) shows that there is a low percentage of amino acid iden-
tity (often <12%), although the activities are comparable and
the sugar transfer reactions follow similar mechanisms. Excep-
tions are ABO transferases, GTA and GTB, that synthesize blood
group A and B, respectively, similarly in human beings and in cer-
tain bacteria, and show about 20% identity. Some of the α2 and
α3/α4-Fuc-transferases also have similar activities when compar-
ing human and bacterial GTs and show 14.5–17.5% identity. This
suggests an exchange of genes between mammals and bacteria or a
common evolutionary origin. The similarity and identity between
GTs with similar function in bacteria or within the eukaryotic GT
families can be much higher. The arrangements of amino acids in
the catalytic site may therefore be similar, leading to the binding
of the same nucleotide sugars and acceptors with the transfer of
the sugar in a specific linkage. The requirement of a metal ion to
stabilize the negative charge of the nucleotide sugar may also be
the same. An evolutionally conserved feature of GTs is that the
catalytic mechanism usually involves a catalytic base.
Inverting GT (52, 57, 58) inverts the anomeric configuration
of the sugar in the donor substrate. This inversion is expected to
follow a single displacement where the catalytic base deprotonates
the hydroxyl group of the acceptor to be glycosylated, which then
becomes an active nucleophile attacking carbon-1 of the sugar
of the donor substrate. This mechanism involves an SN2 reac-
tion and an oxocarbenium ion transition state. Crystal structures
show that the catalytic base (Asp, Glu, or His) is properly posi-
tioned near the hydroxyl to be glycosylated. In many cases, this
catalytic residue is within a conserved DxD motif (Table 5). Both
the DxD motif and the negatively charged phosphate group of
the nucleotide leaving group may be stabilized by a divalent metal
Table 5 | Conserved peptide motifs in glycosyltransferases.
Peptide motif Reference
Many GTs DxD (60)
Beta4-Gal-transferases DxD, GWGxED (60, 61)
Beta3-Gal-transferases DxD, 2 motifs (61)
Fuc-transferases 2-Fuc motif (60, 62, 63)
Two 3-Fuc motifs (60, 62, 63)
6-Fuc motif (60, 62, 63)
Three 2/6-Fuc motifs (60, 63, 64)
HxRRxD
Beta3-GlcNAc-transferases DxD, 2 motifs (61)
C2GnT SPDE (20, 21)
Sialyltransferases, mammalian Sialyl-motif L (65)
Sialyl-motif S (65)
Sialyl-motif VS (65)
Sialyl-motif III (65)
Sialyltransferases, bacterial D(E)-D(E)-G (66)
HP
Polysialyltransferases, mammalian PSTD motif (67)
Polypeptide GalNAc-transferases Ricin-like lectin domain
ABO transferases DxD (60)
ion, but positively charged amino acids could also serve this func-
tion (20). Inverting GTs have been shown to act with a sequential
ordered mechanism.
GTs that retain the anomeric linkage of the nucleotide sugar
may function in a double displacement mechanism (58). Thus,
for retaining GTs, a short-lived glycosyl-enzyme intermediate may
form. This is followed by a shift in protein conformation that
allows a nucleophilic attack on the anomeric center of the sugar
by the deprotonated hydroxyl of the acceptor substrate to be glyco-
sylated, maintaining the original anomeric linkage. A double dis-
placement mechanism has been proposed for GalNAc-transferase
GTA and Gal-transferase GTB, and a covalent glycosyl-enzyme
intermediate through Cys303 was found (68). Other mecha-
nisms may be possible and need to be investigated for retaining
enzymes (58). GTs can also transfer sugar to water and thus have
a nucleotide sugar hydrolase activity.
Mammalian GTs are single or multiple membrane-spanning
proteins in the ER or single transmembrane-spanning type II
membrane proteins in the Golgi, with a short cytosolic domain,
a transmembrane anchor domain, and a stem region that helps
the globular catalytic domain to protrude into the Golgi lumen.
In the bacterial inner membrane, the first enzyme that adds
the sugar-phosphate to P-Und such as WecA, as well as related
sugar-phosphate transferases has multiple membrane-spanning
domains. The remaining bacterial GTs that assemble O antigen
repeating units do not have a transmembrane domain but have
short hydrophobic stretches that may contribute to an association
with membrane components. It is possible that both, mammalian
and bacterial GTs, exist in protein/membrane complexes that acti-
vate enzymes and make the assembly of glycan chains highly
efficient.
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A LARGE FAMILY OF Gal-TRANSFERASES
Families of at least 5 β3-Gal-transferases (B3GALTs) and at least 7
β4-Gal-transferases (B4GALTs) participate in forming the exten-
sions of glycoproteins (69) that are the basis for the attachments of
epitopes including the Lewisx antigen, the selectin ligand involved
in the inflammatory response (8). These inverting metal ion-
dependent GTs have a DxD motif, bind UDP-Gal and a number
of GlcNAc-terminating acceptor substrates.
THE B4GALT FAMILY
The crystal structures of both, human and bovine β4-Gal-
transferases 1 (B4GALT1) in complexes with donor and acceptor
substrates and several mutants, have been thoroughly studied (22).
UDP-Gal binds in a deep catalytic pocket of the bovine B4GALT1
together with Mn2+, in the vicinity of Asp252,Asp318, and Glu317
residues. The conformational change induced by binding UDP-
Gal creates the binding site for GlcNAc-terminating oligosaccha-
rides. The GlcNAc moiety, which needs to be in the β-anomeric
configuration is bound by Phe280, Phe360, Tyr286, Arg259, and
Ile363. The enzyme has three DxD sequences.
In the bovine B4GALT1 enzyme, the first Asp254 residue in
the DVD motif has contact with UDP and Mn2+ but mutations
of Asp318 or Asp320 within the DDD sequence show that these
residues are essential for activity. His344 normally interacts with
Mn2+. A His344Met mutant is active in the presence of Mg2+,
instead of Mn2+ and maintains a closed conformation bound to
Mg2+ and UDP-hexanolamine, allowing an acceptor to bind. The
mutant is, thus, useful to study the role of conformational changes
and the binding of various acceptors (70, 71).
The catalytic domain of B4GALT1 has a short and a larger
flexible loop containing the metal ion binding site. The bind-
ing of the donor and metal ion induces conformational changes
in the long flexible loop, which changes from the open to the
closed conformation, creating a lid over the bound nucleotide
sugar. This opens an acceptor-binding site at the C terminus of
the flexible loop. After the transfer reaction, the loop changes back
to the open conformation, releasing the nucleotide (72). β4-Gal-
transferase 7 (B4GALT7) is another member of the same family,
involved in priming glycosaminoglycan synthesis by adding Gal to
Xylose (24). B4GALT7 also works in an SN2 type mechanism and
changes conformation from closed to open conformation upon
binding UDP and Mn2+. The mammalian β4-Gal-transferases
have a common B4GALT motif GWGxED, which is not found
in β3-Gal-transferases or in the bacterial counterparts of B4GALT
(61) (Table 5).
β4-Gal-transferases that synthesize Galβ1-4GlcNAc sequences
are also found in bacteria. For example, β4-Gal-transferase LgtB
from Helicobacter pylori (Hp) can synthesize Galβ4-S-GlcNAc and
Galβ4-Man linkages (59). The repeating unit of Shigella boydii (Sb)
also contains the Galβ1-4GlcNAc sequence, which is synthesized
by β4-Gal-transferase WfeD (73). The sequences of human β4-
Gal-transferase and WfeD have about 9% identity; yet, the reaction
catalyzed is similar. Both enzymes are inverting GTs, bind UDP-
Gal and GlcNAc-R acceptor substrates, are activated by Mn2+, and
have a DxD motif. Interestingly, we found that both enzymes are
also activated by Pb2+, although the activation of the bacterial
enzyme is much higher and is similar to Mn2+ activation. While
human β4-Gal-transferase is in the GT7 family with a GT-A fold,
the structure and predicted fold of the WfeD in GT family 26
is uncertain (Table 3). The human enzyme does not accept the
negatively charged bacterial acceptor substrate, GlcNAc-PP-lipid,
and vice versa, the bacterial enzyme cannot act on GlcNAcβ-Bn,
which is the standard acceptor for assays of the human enzyme.
Mutagenesis of WfeD showed that the central Glu101 residue
of the DxExE sequence is essential for activity. Lys211 was also
found to be important, possibly by binding one or two phosphate
group(s) of the acceptor substrate (73). Lys residues are appar-
ently not involved in catalysis of the human enzyme. WfeD is not
inhibited by GlcNAcβ-naphthyl, which is a potent inhibitor of the
mammalian β4-Gal-transferase (74).
THE FAMILY OF β3Gal-TRANSFERASES (B3GALT)
Human glycoproteins can be extended with Galβ1–3GlcNAc (type
1) sequences that are also found in O antigens, e.g., in the repeat-
ing unit structure of the E. coli O7 antigen. There are five enzymes
that synthesize the Galβ1–3GlcNAc linkage on a variety of accep-
tors in mammals. They are inverting GTs having a DxD motif
and a requirement for divalent metal ions such as Mn2+ (15, 69).
B3GALT5 has a distinct specificity for O-glycan core 3 (GlcNAcβ1–
3GalNAc-) acceptors. However, crystal structures are not available
for β3-Gal-transferases. Members of the β3-Gal-transferase family
have two common peptide motifs, in addition to the DxD motif
(Table 5).
A β3-Gal-transferase WbbD from E. coli O7 was detected that
can act on GlcNAcα-PP-lipids where apparently the lipid structure
is of minor contribution to the activity (75). The enzyme belongs
to the GT2 family with a predicted GT-A fold and synthesizes the
disaccharide Galβ3GlcNAc α-linked to PP-lipid as the second step
in repeating unit synthesis. Deletion of the enzyme eliminates the
synthesis of O antigen on LPS. This supports the idea that an inhi-
bition of this second step is successful in creating bacteria that are
more susceptible to the mammalian immune system.
BIOSYNTHESIS OF THE THOMSEN–FRIEDENREICH (TF) ANTIGEN
The cancer-associated T antigen, Galβ1–3GalNAc-, core 1, is the
precursor for most O-glycans. In cancer, core 1 is often found
in the unsubstituted form, while in normal glycoproteins, it is
substituted by other sugars and is thus not recognized by anti-T
antibodies. Sialylation of core 1 is also common in glycoproteins
and often overexpressed in cancer and is recognized as the sialyl-T
antigen (15). Several bacteria carry the T antigen as an internal
structure within their O antigen repeating unit. The Shiga toxin
producing O104 serogroup of E. coli is unusual in that it contains
the T antigen in its O antigen repeating unit, as well as the sialyl-T
antigen, sialylα2–3Galβ1–3GalNAc- (ECODAB).
The core 1 structure in human beings is synthesized by core
1 β3-Gal-transferase (T synthase, C1GALT1) and deficiencies of
the enzyme are associated with pathological conditions includ-
ing cancer. T synthase is the only known GT that requires the
co-expression of a chaperone protein, Cosmc, C1GALT1C1 (76).
C1GALT is a GT31 family member with a predicted GT-A fold,
requires Mn2+ for activity and prefers GalNAcα-glycopeptides as
substrates but can also transfer Gal from UDP-Gal to GalNAcα-
benzyl and related substrates (77).
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The GTs responsible for the synthesis of the T antigen in bac-
teria have a similar function (Table 2). The T synthase WbwC in
the E. coli O104 strain is within the GT2 family (Table 3), and has
only 10.5% identity compared to human C1GALT. No chaperone
is necessary for the expression and activity of the bacterial enzyme
(78). Both, human C1GALT and WbwC have a GT-A fold and
DxD motifs, utilize UDP-Gal as a donor and require Mn2+ as a
cofactor. However, in contrast to C1GALT, WbwC has a specificity
for GalNAcα-diphosphate-lipid acceptor, while GalNAcα-peptides
are not substrates. At this time, no crystal structure is available for
T synthases but it is conceivable that the three-dimensional amino
acid arrangements in the catalytic sites are similar. WbwC and
human C1GALT could be distinguished using bis-imidazolium
salt inhibitors, which showed that only WbwC, but not human
C1GALT, was strongly inhibited with IC50 values of 8µM (78).
These inhibitors could selectively attack GTs in pathogenic bac-
teria. However, a potent inhibitor for T synthase has yet to be
discovered (77).
P BLOOD GROUP SYNTHESIS
Human blood group P (Table 1) and related, complex struc-
tures containing the Galα1–4 linkage are synthesized by α4-Gal-
transferases (A4GALT), mainly using glycolipids with Gal residues
as acceptors, e.g., lactosylceramide (79). However, a different α4-
Gal-transferase from pigeon, related to β4-Gal-transferase from
the same species, but not to β4-Gal-transferases from human
beings, has been described that preferably acts on the N-glycans
of glycoproteins (80).
A number of bacteria, including Cj (81), also express an α4-
Gal-transferase with about 11% identity to the human enzyme
(Table 2). The LgtC α4-Gal-transferase from Nm synthesizes the
bacterial mimic of the human P blood group (45). The enzyme is
a member of the GT8 family with a GT-A fold and follows a bi-bi
kinetic mechanism where UDP-Gal binds first. The crystal struc-
ture of LgtC with analogs of UDP-Gal and lactose substrates sug-
gests that Asp103 and Asp105 of one of the four DxD motifs, as well
as His244, are in the vicinity of the donor substrate, while a Mn2+
ion coordinates the phosphates of UDP. The mainly helical C ter-
minus is expected to form hydrophobic and electrostatic interac-
tions with the bacterial membrane. Multiple conformational states
of LgtC with and without bound substrate analogs were found by
methyl-TROSY NMR (82), which is additional information that
cannot be obtained by static crystal structure analysis.
A NEW DxDD MOTIF IN GT2 TRANSFERASES
A new DxDD motif (Table 5), essential for activity, was discovered
in WbwC (78). This motif is also present in WbdN, WfaP, WfgD,
WbgO, WbiP, and CgtB (83–87). All of these GTs in the GT2 family
having a DxDD motif are specific for the transfer of either Gal or
Glc in β1–3 linkage to GalNAc or GlcNAc. Mutagenesis showed
that in WbiP from E. coli O127 (83), the first Asp of the DxDD
sequence was critical for activity while the second contributed but
was not essential. In WbwC from E. coli O104 and O5, all three
Asp residues were mutated and found to be important for activity.
The first Asp (D91) is probably the catalytic base. The other Asp
residues may support the nucleophilic property of the catalytic
base (78).
While WbwC synthesizes the Galβ1–3 linkage attached to the
first GalNAc residue at the reducing end of the O antigen repeating
unit, several other GTs having a DxDD motif in the GT2 family
were shown to synthesize the T antigen at a more internal position
of the repeating unit. These GTs have a different specificity from
that of WbwC and do not require the diphosphate in the acceptor.
The T synthase activities of variants of CgtB from Cj mainly act on
β-linked GalNAc acceptors. Variants of CgtB have distinct accep-
tor specificities (86) and synthesize lipooligosaccharides, which
mimic mammalian glycolipids and glycoproteins.
GlcNAc-TRANSFERASES FORM BACKBONE STRUCTURES
Gal-transferases cooperate with five or more β3-GlcNAc-
transferases (B3GNT) within the GT31 family to form the type
1 and 2 backbone structures of mammalian glycan chains (15,
88, 89) (Table 3). B3GNTs have significant sequence similarity
with Gal-transferases. It is not known if these enzymes are phys-
ically associated, although their combined action would suggest
this. A family of three β6GlcNAc-transferases (IGnT, GCNT2)
then can add 1–6 branches to the linear chains. The β3-GlcNAc-
transferases, but not the β6-GlcNAc-transferases, require divalent
metal ions for activity. No crystal structures are yet available for
B3GNTs.
In the N-glycosylation pathways, GnT I to V (MGAT1 to 5) (12)
are responsible for forming GlcNAc-based antennae that can be
further extended through repeating linear or branched GlcNAcβ1–
3Gal-disaccharides. MGAT1 is an inverting GT with a GT-A fold
within the GT13 family. The crystal structure of rabbit GnT I with
UDP-GlcNAc and Mn2+ supports an ordered sequential mech-
anism. The DxD motif is present as EDD, with Glu211 being
the likely catalytic base (19). MGAT2, 3, 4, and 5 are all invert-
ing GTs and have been classified in the GT16, GT17, GT54, and
GT18 families respectively. Although the GT17 family also con-
tains uncharacterized bacterial proteins, no bacterial equivalents
of MGAT have been found in bacteria.
In the O-glycosylation pathways, the basis of most extended
chains is core 2. Core 2 β6-GlcNAc-transferase C2GnT1 (GCNT1)
adds a branch to O-glycan core 1 to form the core 2 structure
GlcNAcβ1–6(Galβ1–3)GalNAc-R (15). The enzyme has a GT-A
fold and is classified in the GT14 family. The crystal structure of
the catalytic domain of mouse C2GnT1 shows that the protein has
four conserved intramolecular disulfide bonds (20, 21). Cys217,
however, has to be reduced to support the activity, although it
is not an essential residue (90). The human enzyme expressed in
insect cells has two flexible N-glycans that protect the protein from
degradation (91). C2GnT1 is an inverting GT that is active in the
presence of EDTA and does not require Mn2+. The crystal struc-
ture suggests that the conserved, basic amino acids Arg378 and
Lys401 stabilize the diphosphate group of UDP-GlcNAc and thus
serve the function of Mn2+. The structure supports specificity
studies of C2GnT1, showing an absolute requirement for the 4-
and 6-hydroxyl groups of the Gal and GalNAc residues and the 2-
acetamido group of GalNAc (77). Glu320 of the conserved SPDE
sequence may be the catalytic base; it binds to the 4 and 6-oxygen
of GalNAc and could thus deprotonate and activate the 6-hydroxyl
to induce a nucleophilic attack on the C-1 of the GlcNAc moiety
of UDP-GlcNAc (20, 21).
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Bacteria do not appear to have C2GnT or GnT I equivalents, but
they express type 1 of type 2 chains and β3-GlcNAc-transferases
comparable to the mammalian enzymes in their activities. For
example, a β3-GlcNAc-transferase from Hp is involved in the
synthesis of lipooligosaccharides and GlcNAcβ1–3Gal- exten-
sions that resemble mammalian epitopes (92). The β3-GlcNAc-
transferase LgtA from Nm acts on lactose and has a relaxed
donor specificity. It is most active with UDP-GlcNAc but can also
utilize UDP-GalNAc (93). Both, the mammalian and bacterial β3-
GlcNAc-transferases accept a wide variety of acceptor substrates
but have low sequence identity (Table 2) (15).
FUCOSYLTRANSFERASES
Three different types of Fuc-transferases (FUT) are involved in gly-
coprotein biosynthesis. Peptide motifs have been identified that are
specific for α2-Fuc-transferases, α3-Fuc-transferases, or α6-Fuc-
transferases or are shared by α2- and α6-Fuc-transferases (62).
The mammalian α3-Fuc-transferases (FUT3-7,9-11) are invert-
ing enzymes (Table 3) and have two shared motifs with similar
spacing, shared by eukaryotic and bacterial α3FUT. The α2-Fuc-
transferases FUT1 and 2 have less than 30% sequence identity with
their bacterial FUT counterparts, but have well-preserved α2-Fuc-
transferase motifs. There are also similarities between α2- and
α6-FUT (FUT8) (60) with three common motifs (I to III), shared
among eukaryotic and bacterial enzymes (62). The different types
of FUT may have evolved from a common ancestor by divergent
evolution (63).
FUCOSYLTRANSFERASES THAT SYNTHESIZE THE H ANTIGEN
The blood group O (H antigen, Fucα1-2Gal-R) is found in virtu-
ally all human beings and in certain bacteria and is the precursor
substrate structure to form blood groups A and B. The enzymes
that synthesize the H antigen in human beings are inverting
α2-Fuc-transferases 1 and 2 (FUT1 and FUT2) that are closely
related in sequence to the GT6 family ABO transferases GTA
and GTB, although FUT1 and 2 have been classified into a dif-
ferent (GT11) family. FUT1 has a broad acceptor specificity for
Galβ-R while FUT2 prefers O-glycan core 1 (T antigen) as a
substrate (15).
Similar enzymes (Table 2) have been identified in Hp as
FutC (94), in E. coli O86 as WbwK (95), as WbsJ in E. coli
O128 (64), and WbiQ in E. coli O127 (96). WbwK and WbiQ
have a distinct specificity for the T antigen (95, 96) and do not
act on Galβ1–4 glycans. These FUT, therefore, have an activity
resembling that of human FUT2 and have 12–17.5% sequence
identity. HpFucT2 (FutC) adds Fuc preferably to Lewis x accep-
tors but also uses Lewis a and type 1 chains (94). In contrast,
WbsJ prefers acceptors with terminal Galβ1-4Glc structures (64).
WbsJ functions in the absence of divalent metal ion and does
not have a DxD motif. Especially the first Arg residue of the
HxRRxD motif, conserved in α2- and α6-Fuc-transferases, is crit-
ical for activity due to its positive charge. Domain swapping
between WbwK and WbsJ showed that the C-terminal motifs
function in determining acceptor specificity (95). All of the iden-
tified α2-Fuc-transferases have significant homology in GT family
11 (Table 3) with a predicted GT-B fold but none have been
crystallized.
FUCOSYLTRANSFERASES INVOLVED IN THE SYNTHESIS OF LEWIS
ANTIGENS
Lewis type antigens play essential roles in cell adhesion in the
immune system and during inflammation, and aberrant amounts
are often found in cancer. A family of mammalian, inverting
α3-Fuc-transferases (FUT3–7, 9–11) is involved in Lewis antigen
synthesis by linking Fuc to GlcNAc (9, 15, 97, 98). The enzymes
vary in their acceptor substrate specificities and cell type expres-
sion and are in the GT10 family with a GT-B fold. FUT3 is an
exceptional enzyme that has a dual specificity and adds Fucα1–3
on type 2 chains to synthesize Lewis x and y, as well as Fucα1–4
to type 1 chains to synthesize Lewis a and b (Table 1). FUT5 also
shows some α4-Fuc-transferase activity. Human FUT3 and 5 have
Trp111, responsible for type I acceptor recognition and 1–4 link-
age synthesis. FUT that do not have this Trp synthesize the 1–3
linkage (99).
The bacterial α3FUTs show weak homology to mammalian
FUT in two small segments of the catalytic domains (α3FUT
motifs). They have about 10% sequence identity and a com-
mon GT-B fold but no transmembrane domain (25, 62). Two
amphipathic α-helices serve to anchor the enzymes in the mem-
brane. The gastric pathogen Hp is a prime example of expressing
human-like type 1 and type 2 chains that are fucosylated and
include Lewis antigens, which may play a role in adhesion to gas-
tric epithelial cells or in internalization. Hp have short O antigens
(lipooligosaccharides) and the human glycan mimics help to mask
the immunogenic determinants of Hp, thus evading immune sur-
veillance and supporting persistent Hp infections. The different
pH environments in the various regions of the stomach influence
the expression of Lewis antigens, and likely the activities of GTs,
leading to phase variations.
A number of bacteria have Fucα1–4 linkages but Hp is especially
rich in Lewis a, b, x, and y structures and in α3/4-Fuc-transferase
activities (100). All of the eukaryotic and most bacterial α3-Fuc-
transferases are in the GT10 family. Hp has futA and futB genes
encoding α3FUT, in addition to 1-3/4 FUT (FucTa). FucTa has the
CNDAHYSALH sequence near the C terminus that controls type
I chain recognition. It seems that in this α3/4 FUT, it is Tyr instead
of Trp that determines the acceptor preference. Thus, the Y350A
mutant synthesizes Lewis x since it had dramatically reduced α4
FUT activity (100).
The crystal structure of α3-Fuc-transferase from Hp shows that
a Glu95 residue is positioned closely to the anomeric carbon of Fuc
of the donor GDP-βFuc and could be a catalytic base (25) while
Glu249 could stabilize the intermediate oxonium ion. Mutants
in these Glu residues are virtually inactive. Interestingly, tandem
repeats of 7 amino acids (DDLRINY) are found in this α3FUT.
The 2–10 heptad repeats appear to connect the N terminus to
2 amphipathic helices at the C terminus and are thought to be
involved in maintaining secondary structure and activity (101).
The C terminal sequence appears to determine the stability and
overall structure of the protein.
A different α3-Fuc-transferase HhFT2 from Helicobacter
hepaticus (Hh) synthesizes the Lewis x as well as the sialyl-Lewis x
antigen (102). This enzyme is a member of the GT11 family and
has more homology to α2-Fuc-transferases such as WbsJ of GT11,
but less to alpha3/4 FUT in GT family 10. It has 10.4% sequence
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identity with the human enzyme FUT4. HhFT2 has three con-
served motifs, one at the N terminus, one central, and one near
the C terminus (Table 5).
SYNTHESIS OF THE Fucα1-6GlcNAc LINKAGE
The α6-Fuc-transferases add Fuc in α1–6 linkage to the reducing
end GlcNAc of the N-glycan core. The human enzyme (FUT8)
requires the prior action of GnT I and cannot act when the chi-
tobiose of the N-glycan core carries an α3Fuc residue, or if the
internal Manβ residue carries the bisecting GlcNAc. FUT8 is clas-
sified in family GT23 with a GT-B fold. The crystal structure
of human FUT8 shows three domains: an N-terminal coiled-coil
domain, a catalytic domain that resembles GT-B folded GTs, and
a C-terminal SH3 domain, although its significance is unknown.
The C-terminal part of the catalytic domain contains a Rossmann-
like fold with three regions, conserved in α2-, α6-, and other
Fuc-transferases. Both Arg365 and Arg366 are critical for binding
to GDP-Fuc while Asp453 may be a critical catalytic base (26).
A bacterial α6-Fuc-transferase with similar activity in the GT23
family with a GT-B fold and only 8% sequence identity is NodZ
from Rhizobium sp. (Rsp) (Tables 2 and 4) (103). The crystal
structure of NodZ shows two domains of nearly equal size but
with different shape, separated by a central cleft (27). There are
three conserved sequence motifs near the C terminus that play a
role in GDP-Fuc binding or catalysis.
GLYCOSYLTRANSFERASES THAT SYNTHESIZE BLOOD
GROUPS A AND B
The two human ABO transferases that synthesize the antigenic
blood group A and B determinants from the H antigen (α3-
GalNAc-transferase GTA and α3-Gal-transferase GTB, respec-
tively) are homologous retaining enzymes within the GT6 family
with a GT-A fold (Table 3). It is astounding that the critical dif-
ference in donor specificities determining blood group A or B lies
in a difference of only four amino acids. While GTB that transfers
Gal has Gly176, Ser235, Met266, and Ala268, the GTA protein that
transfers the slightly larger GalNAc has mostly smaller amino acids
Arg176, Gly235, Leu266, and Gly268.
In GTA and GTB, two domains are separated by a catalytic
cleft containing the DxD motif (Asp211–Asp213) (39). However,
a highly conserved Glu303 is likely to be the active nucleophile.
UDP binds in the nucleotide sugar-binding domain at the N ter-
minus and the Mn2+ ion coordinates the β-phosphate of UDP. The
H antigen acceptor binds to the C terminus. A disordered and flex-
ible internal loop adjacent to the active site (40) becomes ordered
when the nucleotide (sugar) is bound. This leads to a conforma-
tional change in the protein (43). Two amino acids are in contact
with donor or acceptor in GTA and GTB (39) but only one of
them determines the binding of the nucleotide-bound sugar moi-
ety, i.e., either Gal or GalNAc. Leu266 in GTA has contact with the
acetamido group that allows binding of UDP-GalNAc. Due to the
larger Met in this position (Met266), GalNAc cannot be accom-
modated and, therefore, Gal binds. Ala/Gly268 has contact with
the 3- and 4-hydroxyl groups of Gal and thus does not contribute
to the difference in donor specificity.
Human beings have antibodies against the absent blood group
(A or B), and it is possible that this is induced by bacteria displaying
this blood group. A number of bacterial GTA-like enzymes are
also in the GT6 family and resemble the human counterpart
with relatively high sequence identity of about 20%. The similar-
ities between human and bacterial enzymes suggest a horizontal
gene transfer between species and between bacteria. The bacte-
rial enzymes have an NxN sequence instead of the eukaryotic
DxD motif, and most of these enzymes do not have a metal
ion requirement. Thus, bacterial enzymes may have altered cat-
alytic mechanisms, although there is a strong conservation of
mammalian-type of residues in the active sites (104).
Helicobacter mustelae (Hm) synthesize the blood group A deter-
minant, which reacts with anti-human blood group A antibodies
(105). The enzyme responsible, GTA-like α3-GalNAc-transferase
(BgtA), has 20% sequence identity to its human counterpart GTA
and can act on Fucα1-2Galβ1–3-R or Fucα1–2Galβ1–4-R sub-
strates (Table 2). Thus, bacteria may have acquired the GTA gene
from a mammalian host, enhancing their molecular mimicry,
although it is not clear how the human blood group is giving
them a selective advantage.
The GTA-like enzyme BoGT6a from Bacteroides ovatus (Bo)
(44) and GTB-like α3-Gal-transferase WbnI from E. coli O86
(95) that synthesize blood group B are related to the human
enzymes with significant sequence homology in the GT6 fam-
ily. Both donor and acceptor substrates are the same as those
for GTA and GTB from human beings. The crystal structure of
BoGT6a revealed a disordered region, which becomes ordered
when acceptor Fuc-lactose is bound. This is accompanied by a large
conformational change from the open to a closed state. Isother-
mal titration calorimetry (ITC) experiments showed that BoGT6a
binds UDP-GalNAc with high affinity.
In non-primate mammals and new world monkeys, the lin-
ear blood group B occurs (Galβ1–3Gal-), without the α2-linked
Fuc residue. This structure is foreign to human beings who have
anti-linear B antibodies, thus hindering xenotransplantation. The
α3-Gal-transferase A3GALT that synthesizes the linear B determi-
nant is a homolog of GTA and GTB and has been crystalized with
UDP and Mn2+ (41). The invariable Glu317 was identified as the
catalytic base. The crystal structure in a complex with Galβ-pnp
suggests that Trp residues are critical for binding the natural sub-
strate Galβ1-4GlcNAc (106). The disordered C terminal region is
critical for allowing the substrate to bind (42). Bacterial analogs
of this α3-Gal-transferase remain to be characterized.
SIALYLTRANSFERASES IN MAMMALS AND BACTERIA
Sialyltransferases are ubiquitous in eukaryotes and are also
expressed in certain bacteria (107). These enzymes synthesize sialic
acid linkages commonly found on the non-reducing termini of N-
and O-glycans, and gangliosides as sialylα2–3Galβ1-or sialylα2–
6Gal(NAc)-linkages. In addition, sialylα2–8 linkages are found,
especially in polysialic acids (PSA), which are extremely large, lin-
ear polymers, expressed in a cell type specific, restricted fashion
in embryonic, neuronal, and other selected cell types (108). Sialic
acids contribute to the acidity and hydration of a glycoprotein,
the metal ion binding, and epitope exposure. While sialic acid can
mask the underlying epitope, certain lectins of the immune sys-
tem (e.g., siglecs) directly recognize sialic acid in specific linkages.
Metastatic cancer cells and leukemia cells are often hypersialylated,
www.frontiersin.org October 2014 | Volume 5 | Article 492 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brockhausen Structural and computational glycobiology: immunity and infection
which reduces further processing of glycans and causes glycan
chains to be shorter (15). Sialylation significantly affects the adhe-
sive properties of cells and has also been implicated in the functions
of cell surface receptors (109).
Sialyltransferases are inverting GTs that usually lack a DxD
motif and do not require divalent metal ions. Thus, general
acids and bases identified in the crystal structures of α3- and
α6-sialyltransferases that may interact closely with the substrates
include His residues (28, 33). All known eukaryotic sialyltrans-
ferases have been classified as inverting GT29 with a GT-A fold,
having at least four sialylmotifs (Table 5), a large (L), small (S),
very small (VS), and motif III (65). The L motif contains the donor
binding site while the S motif also binds the acceptor.
Bacterial sialyltransferases are inverting enzymes that bind
CMP-sialic acid donor substrate and acceptors terminating in Gal
or sialic acid but do not have these sialylmotifs and do not belong to
the GT29 family. Instead, they are classified as GT42 (with a GT-A
fold), GT52 or GT80 (with a GT-B fold), and GT38 (polysialyl-
transferases, PSTs). The 6-sialyltransferases (ST6GalNAc) acting
on O-glycans do not appear to have a bacterial counterpart. Two
highly conserved short motifs have been identified in bacterial
PST and other bacterial sialyltransferases (GT52 and GT80), a C-
terminally located HP sequence and a more N-terminally located
D/E-D/E-G sequence (66). Certain bacterial sialyltransferases have
multiple activities, including CMP-sialic acid hydrolase, trans-
sialidase, and neuraminidase activities and are usually from the
GT80 family. Thus, sialyltransferases can be promiscuous with
respect to the linkages they form (or cleave) and the acceptor sub-
strates they recognize. Bacterial sialyltransferases probably evolved
separately from the eukaryotic enzymes, although their functions
and mechanisms can be similar.
ALPHA3-SIALYLTRANSFERASES
In human beings, 6 α3-sialyltransferases (ST3GAL) form
the sialylα2–3 linkage. The expression and activity of α3-
sialyltransferase ST3GAL1 that synthesizes sialyl-T antigen are
increased in breast cancer (110) and appear to promote survival
of cancer cells in the blood (111). In keeping with its activity in
adding a terminal structure, ST3GAL1 is localized to the medial
and late Golgi compartments in human mammary cells (112).
ST3GAL1 acts on glycopeptides with core 1 structure and also
on Galβ1–3GalNAcα-R acceptors that have hydrophobic aglycone
groups. In contrast, a bacterial equivalent, WbwA from E. coli
O104, responsible for the rare occurrence of the sialyl-T antigen
in E. coli, is in the GT52 family with a GT-B fold. WbwA, but
not mammalian ST3GAL1, also has HP and D/E-D/E-G motifs
(Table 5). The crystal structure of porcine ST3GAL1 with CMP
and Galβ1–3GalNAc-acceptor substrate suggests that the essential
His302 interacts with the phosphate of CMP-sialic acid. His319
is the catalytic base in motif III that is proposed to be posi-
tioned near carbon-2 of the sialic acid moiety (28). The conserved
Tyr269 residue interacts with the 4-hydroxyl of GalNAc and thus
determines the enzyme specificity for Galβ1–3GalNAc- over the
Galβ1–3GlcNAc- acceptors.
An α3-sialyltransferase of the GT80 family from Photobac-
terium Phosporeum (Pp) has been crystallized with CMP (29). The
acceptor-binding site has a wide access explaining that a range of
possible disaccharides with Galα and Galβ linkages can form sub-
strates. CMP binds in a cleft between the two domains of the GT-B
fold. The main chain nitrogen of His317 in the HP motif is close to
the nitrogen-4 of Cytidine and the side chain of His317 is near the
oxygen of the phosphate. This suggests a critical role of these His
residues in catalysis. Another α3-sialyltransferase with a GT-B fold
in family GT52 from Nm was crystallized (31) with the donor ana-
log CMP-3F-Neu5Ac. Asp258 could be a general base and His280
(within the HP motif) a general acid.
ALPHA6-SIALYLTRANSFERASES
Human α6-sialyltransferases add sialic acid to the Gal termini
of N-acetyllactosamine chains of N-glycans. ST6GAL1 is highly
expressed in colon cancer and metastatic cells (113) and also
resides in the trans-Golgi (114). A homolog with 48% sequence
identity (ST6GAL2) is mainly expressed in the brain and has
the additional ability to synthesize sialylα2–6GalNAcβ1–4GlcNAc-
structures (115). Human ST6GAL1 is a glycoprotein stabilized by
three disulfide bonds (33). The catalytic residue, His370, deproto-
nates the 6-hydroxyl of Gal, generating an active nucleophile that
attacks the carbon-2 of sialic acid. The reaction follows a random-
order mechanism of substrate binding. Rat ST6GAL has three
disulfide bonds and two N-glycans (32). As many GTs, the enzyme
has a disordered loop, and His367 is the catalytic base within the
sialyl motif VS.
The bifunctional bacterial α6-sialyltransferase PM0188 from
Pasteurella multocida (Pm) of GT family 80 has 14.6% sequence
identity to human ST6GAL1. The crystal structure showed the
GT-B fold and that Asp141, His311 (within the HP motif), Glu338,
Ser355, and Ser356 were important for catalysis (37). The Photo-
bacterium sp. (Psp) α6-sialyltransferase was also crystallized with
CMP and lactose (35). The enzyme is in the GT80 family with a
GT-B fold and has three domains, with the donor and acceptor
bound between domains 2 and 3. Asp232 (within the D/E-D/E-G
motif) is near the 6-hydroxyl of Gal while the nitrogen of His405
(within the HP motif) is close to the phosphate-oxygen. Thus,
Asp232 could be a catalytic base that deprotonates the 6-hydroxyl
of Gal, and His405 could be a catalytic acid that protonates the
donor substrate.
MULTIFUNCTIONAL SIALYLTRANSFERASES
In bacteria, mimics of human sialylα2-3/6/8Galβ1- structures
occur, e.g., in the lipooligosaccharides of Gram-negative bacte-
ria such as Cj (116, 117). Cells of the human nervous system
are rich in gangliosides as well as glycoproteins containing simi-
lar sialyl-linkages. Thus, after bacterial infections, cross reactivity
of antibodies could cause the rare development of neurolog-
ical disorders. Guillain–Barré syndrome is an example (118).
Cj expresses a bifunctional α3/8-sialyltransferase CstII and an
α3-sialyltransferase CstI, which are responsible for the molecu-
lar mimicry of Cj in their lipooligosaccharide structures. Both
enzymes have a predicted GT-A fold within the GT42 family. The
structure of CstI shows (30) that His 202 is the catalytic base. Sim-
ilarly, His188 is likely the catalytic base in CstII that deprotonates
the 3-hydroxyl of Gal, which then attacks carbon-2 of sialic acid
of the donor (119). The flexible lid in the CstII protein becomes
ordered in a closed form when CMP binds (36). The acceptors
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lactose (for α3-sialyltransferase activity) or sialyl-lactose (for α8-
sialyltransferase activity) bind in a cleft and Arg129, Asn51, and
Tyr81 contribute to the binding of the sialylated acceptor. The role
of His188 as a catalytic base in CstII has also been confirmed by
NMR studies (120). The intrinsic pK a values of His188 were mea-
sured in monomeric mutants by determining the pH-dependent
chemical shifts of [13C]-labeled His188.
The monofunctional sialyltransferases function with similar
mechanisms compared to the mammalian enzymes. Multifunc-
tional enzymes, however, are primarily found in bacteria and
include the α3-sialyltransferase PmST1 from Pm, which binds
CMP-sialic acid as donor and lactose, Gal, GalNAc as well as sialic
acid as acceptor. The crystal structure shows that binding of CMP-
sialic acid donor substrate causes a change in conformation and
opens the acceptor-binding site. The activities of PmST1 function
optimally at different pH values. It has a GT-B fold within the GT80
family (Table 3). The crystal structure shows that Asp141 is the
catalytic base (34) with His112 also being important for enzyme
activity. Another multifunctional α3-sialyltransferases PdST from
Pasteurella dagmatis (Pd) in the GT80 family with a GT-B fold
is also a CMP-sialic acid hydrolase. At low pH, it can act as a
trans-sialidase and a sialidase (121).
POLYSIALYLATION
Important sialic acid structures are the PSA, found in human neu-
ronal and other selected cell types (107). Only a selected number of
proteins carry the PSA modification (122). For example, polysia-
lylated neural cell adhesion molecule N-CAM is prominent in the
developing nervous system but also occurs in leukocytes with roles
in the regulation of cell adhesion. N-CAM becomes anti-adhesive
when long polymers of α2–8-linked sialic acids are covalently
attached to its N-glycans (108). The sialylα2–8 linkages of PSA
are synthesized based on sialylα2–3/6Gal residues of N-glycans by
developmentally regulated PSTs, which are highly expressed in the
developing and embryonic brain (123). Neuropilin-2 (NRP2) is a
glycoprotein containing multiple N-glycosylation sites, as well as
O-glycans with sialylated core 1 and 2 structures. In cells lacking
core 2, human PST (ST8SiaIV) was shown to assemble PSA on
sialylated core 1 chains of neuropilin (124). The presence of these
PSA polymers extends the half-life of proteins.
E. coli and Nm are examples of bacteria that carry sialylα2–8
polymeric PSA capsules, which help bacteria to resist phagocy-
tosis. These PSA capsules mimic the eukaryotic chains, although
they are linked to the membrane via a lipid anchor, and may have
bacteria-specific modifications such as O-acetylation (125). The
large, charged and hydrated polymeric enzyme product is assem-
bled in the cytoplasmic compartment and then extruded through
the membranes by ABC transporter and export systems (Figure 3).
PSA confers a selective advantage to bacteria in the human nervous
system and is associated with meningitis or other neurological
conditions. Bacteria may also have PSA with α2–9 linkages or
alternating α2–8 and α2–9 linkages.
In mammals, PSTs synthesize PSA by the addition of individual
sialic acid residues in a processive fashion. Like the other sialyl-
transferases, mammalian PSTs are inverting enzymes of the GT29
family (Table 3). In addition to four sialyl motifs, ST8SIAII and
ST8SIAIV (formerly STX and PST, respectively) have a unique,
conserved, polybasic PST domain (PSTD motif) (Table 5) (67),
which is absent from the other types of sialyltransferases. Basic
residues in the PSTD motif are responsible for acceptor substrate
recognition (126, 127).
In bacteria, the PSA capsule is synthesized by GT38 family PST
that are inverting enzymes. In E. coli, PST has only 5.4% sequence
identity with the human enzyme (128). The human PST equiv-
alent from Nm has <10% sequence identity with human PST
and has a requirement for Mg2+ (129). Kinetic experiments of
His and Pro mutants of the PST from Nm suggested that the HP
motif contributes to CMP-sialic acid but not acceptor binding. The
acceptors can be a glycolipid containing two sialic acid residues as
a primer. Gal-terminating glycans of glycopeptides, including the
T antigen linked to Ser, also served as acceptor substrates for the
PST form Nm. Different PSTs synthesize either the α2–8 or α2–9
linked polymers of bacterial PSA capsules.
METHODS TO STUDY GLYCOSYLTRANSFERASE PROTEIN
STRUCTURES AND FUNCTIONS
It is often difficult to produce sufficient pure enzyme in order to
analyze protein structure by X-ray crystallography. In addition,
the protein may not show exactly the same properties in a crystal,
compared to solution and body fluids. To approximate the pro-
tein structure present in the natural environment, protein NMR
studies have been helpful (130). Enzyme substrate or inhibitor
interactions have been determined by biochemical kinetics studies
but can also be studied by MS and Saturation Transfer Difference
(STD) NMR (131, 132). Conformational dynamics of proteins
to understand molecular recognition can be achieved by molec-
ular dynamics simulation and docking programs, which requires
knowledge of protein structure. Theoretical modeling has been
undertaken to predict protein structure, substrate binding, and
dynamic properties of GTs. Thus, the three-dimensional interac-
tions between substrates and enzyme protein, cofactor binding
sites, ligand flexibility, and movements can be estimated by com-
putational methods (133, 134). Multivariate data analysis of the
amino acid property patterns also helps to predict a protein fold
(135).
New enzymes can be designed based on knowledge of protein
structure and substrate binding. For example, the blood group B
GTB Gal-transferase has been re-designed with a model Epimer
Propensity Index (EPI) to transfer Glc instead of Gal (136). The
orientation of the sugar donor in the folded enzyme is highly con-
served. The R228K mutant of β4GalT1 has higher Glc-transferase
activity due to the inability to effectively bind the axial 4-hydroxyl
of Gal (23). Similarly, GTB modeling correctly predicted a higher
Glc-transferase activity of GTB in the presence of the unnatural
UDP-Glc donor upon increasing the sizes of Ser185 to Asn and
Cys (136).
One approach to developing good GT inhibitors is to obtain
qualitative and quantitative information on the substrate binding
sites from NMR spectroscopy. STD NMR measures the signals
of the unbound substrate, which is then compared to those of
the bound substrate. Saturation transferred from the enzyme to
specific sites of the bound substrate is seen as an attenuation of
resonance signals. The difference spectra at different ligand con-
centrations allow to identify the bound substrate and to determine
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the binding affinity. In spin-lock filtering experiments, transverse
relaxation of substrate signals is recorded, which is enhanced
when the ligand is bound. Thus, signals are attenuated upon lig-
and binding. This process can be enhanced by using spin labels.
The conformations and relative placements of bound GnT V sub-
strates have been determined using transferred NOE and STD
measurements (137).
In addition to these NMR experiments, surface plasmon reson-
sance (Bioacore) experiments can be used to determine the bind-
ing affinities (132). The ligand binding ability of GTs with and
without donor or a number of potential inhibitors can be assessed
with biotinylated substrates bound to a streptavidin-coated chip.
The binding of donor and acceptor analogs to the blood group B
enzyme GTB has also been analyzed by ITC combined with STD
NMR titration (138). The results show the binding stoichiom-
etry and binding affinity of one donor and acceptor molecule
per protein, the thermodynamics, enthalpy, and entropy changes
upon binding as well as the dissociation constants. The study
also emphasizes that there can be differences in binding substrate
analogs that should be considered.
Electrospray-mass spectrometry (ES-MS) has been used to
determine the thermodynamics and affinities of substrates (139).
Association constants were measured from the relative abundance
of ions in the EI-MS spectra for GTA and GTB in aqueous solu-
tion with native donor and acceptor substrates as well as substrate
analogs, products, and metal ion cofactor. To confirm the retain-
ing mechanism of the enzymes, a mutant of blood group A
(GTA) GalNAc-transferase in solution containing UDP-GalNAc
and Mn2+ was studied, as well as the similar mutant of GTB.
The catalytic Glu303 was replaced with Cys. After Trypsin diges-
tion, a covalent intermediate could be trapped. Thus, tandem
MS using collision-induced dissociation confirmed that Cys303
in both GTA and GTB enzymes was responsible for forming
the glycosyl-enzyme intermediate. The formation of trisaccha-
ride product can also be proven by MS (68). Thus, the double
displacement mechanism of these retaining GTs was supported
by MS.
GLYCOSYLTRANSFERASE INHIBITORS
Detailed knowledge of GT structure and function is the basis for
the development of effective GT inhibitors that may re-direct
glycan biosynthesis. GT substrates usually bind through a small
number of essential hydrogen bonds or hydrophobic interactions.
Thus, not all of the substituents of the donor sugar, the base of
the nucleotide, or the sugars of the acceptor are critically involved
in binding (140). Therefore, modifications of these residues can
result in competitive inhibitors that still bind in the catalytic site
but do not support catalysis. Inhibitors can be ligands that bind
well to the enzyme but cannot be released easily, or interfere
with catalysis either as donor substrate analogs, acceptor sub-
strate analogs, transition state analogs, compounds that prevent
conformational changes necessary for catalysis, or compounds
that distort protein conformation (74, 77, 103). Small structural
modifications of compounds can have a dramatic effect on their
inhibitory activity. Inhibitors have been designed that interfere
with conformational changes and flexible loop movements that
are essential events for substrate binding and catalysis (141). Sugar
donor analogs for ABO transferases (GTA and GTB), carrying a
substituent at the uracil moiety, block the stacking of amino acids
required for the proper folding of the internal loop. A heterocyclic
compound inhibited GTB by interfering with its ability to bind
metal ion, as well as donor and acceptor substrates. The compound
does not appear to be structurally related to the acceptor but partly
binds in the acceptor-binding site (142). A combination of crystal
structure, Biacore, STD NMR, and docking experiments suggested
that the inhibitor competes with binding of Fuc of the acceptor
and the Mn2+ ion. Non-competitive inhibitors have also been
described that potentially alter the structure of the enzyme leading
to inactive proteins (77, 78). Modified nucleotide sugars are often
recognized by GTs leading to transfer of unnatural sugars (143).
Fluorescent groups modifying the base of the sugar-nucleotide can
be useful as indicators of binding (144).
CHEMOENZYMATIC SYNTHESIS OF SHARED EPITOPES
The preparation of bacterial GTs that lack a transmembrane
domain is relatively inexpensive and they can be used in chemoen-
zymatic synthesis not only of bacterial glycoconjugates but also
for mammalian oligosaccharides and glycoproteins with specific
epitopes (Table 1). Due to the variety of bacterial enzymes with
different specificities, a diverse range of glycan structures can be
synthesized and processed for use as vaccine, to prepare anti-
bodies for passive immunity, and for further studies of glycan
functions. Examples include the synthesis of the complete blood
group Forssman antigen GalNAcα3GalNAcβ3Galα4Galβ4Glc-p-
nitrophenyl by β3-GalNAc-transferase and α4-Gal-transferase
from Cj, followed by α3-GalNAc-transferase from Pm (81,
140). The assembly of the entire blood group B determi-
nant was achieved using GTs from E. coli O86 (145). Bacte-
rial enzymes α4-Gal-transferase LgtC, β3-Gal(NAc)-transferase
LgtD, and α2-Fuc-transferase WbsJ (146) efficiently synthesized
the tumor-associated epitope Globo-H-hexasaccharide (Fucα2-
Galβ1–3GalNAcβ1–3Gaαl–4Galβ1–4Glcβ-benzyl).
Knowing the amino acids and mechanisms involved in sub-
strate binding and catalysis, bacterial enzymes or new mutant
enzymes can be engineered for use in the production of new nat-
ural or unnatural glycan structures, or for more efficient synthesis
of known structures (147). For example, new donor specificity can
be engineered by mutating only one or two critical amino acids
that convert the function of the enzyme (140, 148).
Phosphorylases can also reversibly form glycosidic linkages
(149). They can have similarity to either inverting or retaining gly-
cohydrolases or to GT-B-folded retaining GT (CAZy). Sugar-1-P
can be used as a substrate for phosphorylases to produce a wealth
of different glycans with regio-selectivity. An interesting combi-
nation of chemical and enzymatic synthesis of the T antigen and
the Galβ1–3GlcNAc linkage has been achieved using a combina-
tion of galactokinase (GalK) from E. coli that synthesizes Gal-1-P,
and a Galβ1–3 HexNAc phosphorylase from Bifobacterium infan-
tis that has promiscuous acceptor specificity (150). These enzymes
could add Gal in the presence of ATP to synthetic GalNAc- and
GlcNAc- substrates with various aglycone groups. The phospho-
rylase has multiple DxD motifs and an Asp-rich domain at the
C terminus. The T antigen was also synthesized from sucrose
and GlcNAc using phosphorylase from Bifidobacterium longum
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(151) together with sucrose phosphorylase, UDP-Glc-hexose-1-P
uridyltransferase and UDP-Glc 4-epimerase.
Glycosidases catalyze reversible reactions and have also been
used to form sugar linkages using high concentrations of reac-
tants. Glycosidases act with an inverting or retaining mechanism,
utilizing a catalytically active nucleophile in the active site such as
Asp or Glu. Mutant glycohydrolases that lack the catalytic base as
well as hydrolase activity can be used to efficiently transfer a sugar
to an acceptor substrate and synthesize specific linkages (glycosyn-
thases). For example, large N-glycan-type oligosaccharides can be
transferred to the GlcNAc residue linked to Asn of glycoproteins
by a mutant endo-glucosaminidase that normally cleaves the chi-
tobiose and releases the N-glycan. Thus, engineered glycosidases
can be stereo-selective and very useful in achieving high yields of
complex glycans (152).
CONCLUDING REMARKS
It is astounding that proteins can be so different in amino acid
sequence and yet become similar specific and effective catalysts
for the transfer of sugars to proteins, lipids, and sugars and only
have two major protein folds. Many possibilities are there for bind-
ing of donor and acceptor substrates but the transfer only involves
inversion or retention of the anomeric configuration of the sugar.
Mechanisms common to eukaryotes and bacteria include a change
in protein conformation upon nucleotide sugar binding facilitat-
ing acceptor binding, and the action of a base (Glu, Asp, His)
that deprotonates the hydroxyl to be glycosylated, which then
becomes a nucleophile that results in cleavage of the sugar from
the donor substrate. Bacterial and mammalian enzymes are often
comparable in their action so that mammalian epitopes can easily
be synthesized with bacterial enzymes, for example, to produce
vaccines for cancer. However, the bacterial world is much more
complex, variable, and challenging. Knowledge of bacterial GTs
can lead to the synthesis of glycans, enzyme substrates, and anti-
gens to study their biological functions and role in disease and
to synthesize vaccines against specific pathogenic strains of bac-
teria. Bacteria may have evolved to express the GTs that make
human-like structures, giving them a selective advantage. Most
of the time, bacteria and human beings are symbiotic or com-
patible but once in a while, the mimicry of bacteria can lead
to infection and serious consequences. We speculate that bacte-
rial and mammalian enzymes with similar functions may have
evolved in parallel, or may be derived from an ancient com-
mon ancestor. There may have been exchange of genes between
these species (horizontal gene transfer), or GTs may be derived
by convergent evolution. The many similar genes of a particu-
lar family may have been derived by gene duplication from an
ancestral gene.
Further detailed understanding of GT structures and mecha-
nisms helps to visualize how amino acids cooperate in forming a
catalytic site, predict their functions, and to gain valuable insight
into the syntheses of complex glycans in mammals and in our
close neighbors, bacteria. Both, the bacterial world and human
beings can benefit from this relationship. In addition, inhibitors
of bacterial GTs may help to eliminate virulence factors, and
this is an urgently needed goal in light of growing antibiotic
resistance.
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